Press Releases | Vertex Pharmaceuticals Newsroom

Date	Title	Additional Format
Feb 23, 2004	Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors - Study Published in Nature Medicine -	Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors
Feb 13, 2004	Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange Cambridge, MA, February 13, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has completed the exchange of approximately $153 million in aggregate principal amount of its 5% Convertible	Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange
Feb 11, 2004	Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.	Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004
Feb 10, 2004	Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007 Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007 Cambridge, MA, February 10, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that five holders of its existing 5% Convertible	Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007
Feb 03, 2004	Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference -Company to Provide Financial Guidance for 2004-	Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Feb 03, 2004	Vertex and Novartis Amend Drug Discovery and Development Collaboration Vertex and Novartis Amend Drug Discovery and Development Collaboration Cambridge, MA, February 3, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex and Novartis Pharma AG have amended their collaboration directed at targets in the protein kinase gene family.	Vertex and Novartis Amend Drug Discovery and Development Collaboration
Jan 29, 2004	Vertex Researchers Publish Structure of FLT-3 Kinase in Molecular Cell -Potential Mechanism Underlying Various Types of Leukemia Described-	Vertex Researchers Publish Structure of FLT-3 Kinase in Molecular Cell
Jan 20, 2004	Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) Cambridge, MA and Research Triangle Park, NC, January 20, 2004 -- The final 48-week results from the NEAT trial, an open-label, multi-center study	Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS)
Jan 12, 2004	Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Cambridge, MA, January 12, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan	Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference
Oct 24, 2001	Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 — Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.	Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results